Researchers question WHO guidelines on non-sugar sweeteners, citing a reliance on biased prospective cohort studies over randomized controlled trials. The study calls for an urgent re-evaluation of WHO’s stance, as recent evidence suggests non-sugar sweeteners may actually reduce cardiometabolic risks.
AstraZeneca launches GLP-1 combo to treat obesity co-morbidities
Share this article AstraZeneca has announced its strategy for the cardiometabolic market, in particular for treating obesity. Credit: encierro via Shutterstock. AstraZeneca has announced its
November 14, 2023